|
| | APOMORPHINE HYDROCHLORIDE Basic information |
| Product Name: | APOMORPHINE HYDROCHLORIDE | | Synonyms: | (-)-apomorphiniumhydrochloride;(r)-id;(theta)-id;(-)-APO H CL;4H-Dibenzode,gquinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, hydrochloride, (6aR)-;Apomorphine hydrochoride;g)quinoline-10,11-diol,5,6,6a,7-tetrahydro-6-methyl-4h-dibenzo(dhydr;R()-Apomorphine hydrochloride,R(–)-10,11-Dihydroxyaporphine, R(–)-APO | | CAS: | 314-19-2 | | MF: | C17H18ClNO2 | | MW: | 303.78 | | EINECS: | 206-243-0 | | Product Categories: | | | Mol File: | 314-19-2.mol |  |
| | APOMORPHINE HYDROCHLORIDE Chemical Properties |
| Melting point | >250℃ | | storage temp. | Store at RT | | solubility | ≥1.08 mg/mL in EtOH with ultrasonic; ≥12.9 mg/mL in DMSO; ≥5.12 mg/mL in H2O | | form | solid | | EPA Substance Registry System | Apomorphine hydrochloride (314-19-2) |
| RIDADR | 3249 | | HazardClass | 6.1(b) | | PackingGroup | III | | Toxicity | mmo-sat 20 mg/plate MUREAV 137,17,84 |
| | APOMORPHINE HYDROCHLORIDE Usage And Synthesis |
| Originator | Apomorphine
hydrochloride,Nastech
Pharmaceuticals
Company, Inc. | | Uses | Emetic. | | Uses | (R)-(-)-Apomorphine Hydrochloride is a prototypical dopamine agonist. Potential treatment for Parkinson’s disease. | | Manufacturing Process | 2 Methods of producing of apomorphine
1. The apomorphine was obtained by dehydratation of morphine at heating to
120°C in the presence phosphoric acid and rendering of HCl gas over reaction
mixture.
2. The morphine was converted to β-chloromorphine and then to
dichlorodihydrodesoxymorphine at heating to 140°-150°C in the presence
hydrochloric acid. Then apomorphine is obtained by dehydratation of
dichlorodihydrodesoxymorphine. | | Brand name | Apokyn
(Vernalis). | | Therapeutic Function | Emetic, Expectorant, Hypnotic, Antiparkinsonian,
Dopamine agonist | | General Description | Apomorphine hydrochloride,(6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolone-10,11-diol hydrochloride (Apokyn), is awhite or off-white powder or crystal soluble in hot water(pKa＝8.92). Apormorphine is an aporphine alkaloid of thebenzoquinoline class. Oral apomorphine is poorly absorbedand has a bioavailability of less than 4%. Upon subcutaneousadministration, apomorphine is completely absorbed. Within10 to 20 minutes, the maximum concentration of the drug isdistributed from the blood plasma to the CSF. Other potentialroutes of administration include continuous subcutaneous infusion,intravenous infusion, intranasal spray application,sublingual, and rectal administration.23 The agent is highlylipophilic in nature, allowing for rapid diffusion across theBBB after injection. Apomorphine has a short plasma halflife;however, clinical effects may last from 60 to 90 minutes.Apomorphine displays a significant degree of interpatientvariability in its pharmacokinetic profile. Studies of bothintravenous and subcutaneous injection routes found this variation was not attributable to body weight, age, gender,and duration of PD or L-DOPA dose/duration alone.Apomorphine is extensively metabolized. Hypothesizedroutes include sulfation, N-demethylation, glucuronidation,and oxidation. Subcutaneous injections of apomorphine arerenally and hepatically cleared, with the majority appearingto be renally cleared. Dosage adjustments are needed in bothliver and renal impairment. The activity of apomorphine isbelieved to be caused by stimulation of postsynaptic D1- andD2-type receptors within the caudate/putamen in the brain.Apomorphine is indicated for the acute, intermittent treatmentof hypomobility, “off” episodes (“end-of-dose wearingoff” and unpredictable on/off episodes) associated with advancedPD. | | Biological Activity | Prototypical dopamine agonist (pK i values are 6.43, 7.08, 7.59, 8.36 and 7.83 for human recombinant D 1 , D 2L , D 3 , D 4 and D 5 receptors respectively). Produces biphasic effects on locomotor activity, and displays anti-Parkinsonian and neuroprotective actions following systemic administration in vivo . | | Clinical Use | Treatment of refractory motor fluctuations in Parkinson’s
disease | | Safety Profile | Poison by intravenous andintraperitoneal routes. Mutation data reported. When heated to decomposition itemits very toxic fumes of NOx and HCl. | | Veterinary Drugs and Treatments | Apomorphine is used primarily as an emetic in dogs, and is considered
the emetic of choice for dogs by many clinicians. It is sometimes
used in cats, but its use in this species is somewhat controversial. | | Drug interactions | Potentially hazardous interactions with other drugs
Antihypertensives: enhanced hypotensive effect.
Domperidone: possible increased risk of ventricular
arrhythmias.
5HT3
-receptor antagonists: possibly increased
hypotensive effects with ondansetron.
Nitrates: enhanced hypotensive effect. | | Metabolism | After subcutaneous injection its fate can be described by
a two-compartment model, with a distribution half-life of
5 (±1.1) minutes and an elimination half-life of 33 (±3.9)
minutes. Clinical response correlates well with levels of
apomorphine in the cerebrospinal fluid.
Apomorphine is extensively metabolised in the liver,
mainly by conjugation with glucuronic acid or sulfate;
the major metabolite is apomorphine sulfate. It is also
demethylated to produce norapomorphine.
Most of a dose is excreted in urine, mainly as metabolites. | | storage | Store at RT |
| | APOMORPHINE HYDROCHLORIDE Preparation Products And Raw materials |
|
